Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
58 hedge funds and large institutions have $318M invested in Oyster Point Pharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 11 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
5% less funds holding
Funds holding: 61 → 58 (-3)
5% less capital invested
Capital invested by funds: $336M → $318M (-$17.6M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.57M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.27M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.16M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$941K |
| 5 |
State Street
Boston,
Massachusetts
|
+$610K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.45M |
| 2 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$2.28M |
| 3 |
JP Morgan Chase
New York
|
-$1.37M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$529K |
| 5 |
LP
Lexington Partners
New York
|
-$501K |
OYST Hedge Fund Activity: Q2 2021 in Review
58 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q2 2021, worth a combined $318M — down 5.3% from $336M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OYST and 8 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 20 added.
The largest buyer was BlackRock, adding an estimated $4.57M. The largest seller was Citadel Advisors, cutting an estimated $2.45M.
- 58 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q2 2021, down from 61 in Q1 2021.
- Funds reported $318M of Oyster Point Pharma, Inc. Common Stock stock for Q2 2021, down 5.3% quarter-over-quarter.
- 8 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q2 2021 and 11 closed out, a net change of -3 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $4.57M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q2 2021 was Citadel Advisors, an estimated $2.45M sold.
Based on aggregated 13F filings for Q2 2021.